Palisades Compounding Pharmacy, Pacific Palisades, CA

Is Palisades Compounding Pharmacy registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Palisades Compounding Pharmacy hold a California pharmacy license?

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones.

Has Palisades Compounding Pharmacy had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Sep 27, 2023) and 1 FMD-145 letter (Aug 9, 2024) for Palisades Compounding Pharmacy. State board actions: record found. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses lists “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for three years subject to the terms and conditions in the decision” dated Apr 1, 2026, case AC 7915 on license PHY 48986.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Palisades Compounding Pharmacy
Location
Pacific Palisades, CA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Aug 9, 2024
FDA Data Dashboard inspections
1 inspection: 1 VAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 2 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Palisades Compounding Pharmacy, a 503A facility, with 3 dated actions.

Document
Aug 9, 2024FMD-145 letterFMD-145 Letter Issued 08/09/2024Not linked by FDA
Sep 27, 2023Untitled letterUntitled Letter (9/27/2023)FDA copy (archived)
Mar 15, 2023Form 483483 Issued 03/15/2023FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Palisades Compounding Pharmacy, Pacific Palisades, CA (FEI number 3008174851), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Mar 15, 2023Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30081748511199968

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 2 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Feb 23, 2023 to Mar 15, 2023: 2 observations

Firm on the cover
Palisades Compounding Pharmacy, 540 Palisades Dr, Pacific Palisades, CA 90272
FEI number
3008174851
Establishment type on the cover
Producer of Non-Sterile Drugs
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You produced hazardous drugs without providing adequate segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically, the hood, utensils, mortar and pestle, unguator and other equipment used to produce hazardous products are not adequately cleaned, to include the deactivation of hazardous products, between batches to prevent cross-contamination.

For example, your firm dispensed prescriptions for Rx# <Redacted B4>, Progesterone (50 mg) capsules; Rx# <Redacted B4>, Progesterone (200 mg/~ cream; Rx <Redacted B4> )(C~ Estradiol (8mg/gm) cream; Rx# <Redacted B4>. <Redacted B4> Estrogen (3.5 mg/gm)J gel· Rx# <Redacted B4> , Testosterone <Redacted B4> cream; Rx <Redacted B4> Testosterone (2 mg/gm) gel; Rx <Redacted B4> <Redacted B4> Estriol (2 mg/gm) cream; Rx~<Redacted B4> Estriol (5 mg/gm) cream on your firm's equipment without using a deactivator between each product produced.

Observation 2

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

Specifically, your firm used the following expired excipients in the production of the finished drug product with . lot# 12262022@ <Redacted B4> produced on 12/26/2022 and filled on 1/18/2023 for Rx # <Redacted B4> (7RC1 Benzocaine 20%/Lidocaine 10%/Tetracaine 10%" with an expiry/use by date of 06/26/2023 :

a,<Redacted B4> Lot # <Redacted B4> expiration 12/25/2022

State board of pharmacy records

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.

Board actions

As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.